Chardan Capital Raises Esperion Therapeutics (ESPR) Price Target to $75.00
Esperion Therapeutics (NASDAQ:ESPR) had its target price boosted by Chardan Capital from $20.00 to $75.00 in a research note issued to investors on Wednesday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
Other equities analysts also recently issued reports about the company. Jefferies Group upgraded Esperion Therapeutics from a hold rating to a buy rating and reduced their target price for the stock from $85.00 to $55.00 in a research report on Tuesday, August 8th. Stifel Nicolaus reiterated a buy rating and set a $70.00 target price (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research upgraded Esperion Therapeutics from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Bank of America reiterated a neutral rating and set a $60.00 target price on shares of Esperion Therapeutics in a research report on Friday, August 11th. Finally, Needham & Company LLC increased their target price on Esperion Therapeutics from $58.00 to $72.00 and gave the stock a positive rating in a research report on Tuesday, August 8th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Esperion Therapeutics currently has a consensus rating of Buy and an average target price of $60.15.
Esperion Therapeutics (NASDAQ ESPR) traded up $2.30 during midday trading on Wednesday, reaching $56.97. The company had a trading volume of 483,024 shares, compared to its average volume of 537,050. Esperion Therapeutics has a 1 year low of $10.71 and a 1 year high of $65.20.
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period in the previous year, the firm posted ($0.77) earnings per share. analysts predict that Esperion Therapeutics will post -7.3 EPS for the current fiscal year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the sale, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 32.50% of the company’s stock.
A number of large investors have recently made changes to their positions in ESPR. Iguana Healthcare Management LLC grew its stake in shares of Esperion Therapeutics by 50.0% in the third quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biopharmaceutical company’s stock valued at $7,518,000 after buying an additional 50,000 shares in the last quarter. California Public Employees Retirement System grew its stake in shares of Esperion Therapeutics by 14.9% in the third quarter. California Public Employees Retirement System now owns 48,158 shares of the biopharmaceutical company’s stock valued at $2,414,000 after buying an additional 6,258 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $540,000. Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $12,583,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $715,000. Institutional investors own 92.27% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/chardan-capital-raises-esperion-therapeutics-espr-price-target-to-75-00/1754258.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.